Appeal Court rules that NICE procedure was unfairBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39574.351782.DB (Published 08 May 2008) Cite this as: BMJ 2008;336:1035
- Clare Dyer
The hopes of people with mild Alzheimer’s disease of having access to acetylcholinesterase inhibitors through the NHS were boosted last week when three appeal court judges ruled that a key step in the process for appraising the drugs for NHS use was “procedurally unfair.”
The court unanimously overturned a High Court ruling that the National Institute for Health and Clinical Excellence (NICE) acted fairly when it refused to supply the drug company Eisai with a full version of the computer model it used to decide that the treatment would not be cost effective for the early stages of the illness (BMJ 2007;335:319; doi: 10.1136/bmj.39307.630347.DB).
The drugs cost £2.50 (€3.17; …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial